losartan has been researched along with simvastatin in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (45.10) | 29.6817 |
| 2010's | 25 (49.02) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cao, Z; Cooper, ME; Hu, L; Liu, J; Qin, J; Sun, L; Zhang, Z | 1 |
| Diener, HC | 1 |
| Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A | 1 |
| Daniel, WG; Eskafi, S; Gabler, C; Garlichs, CD; Illmer, T; Lorenz, HM; Roerick, O; Schmeisser, A; Soehnlein, O; Strasser, R | 1 |
| Ahn, JY; Ahn, TH; Choi, IS; Chung, WJ; Han, SH; Kang, MH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK | 1 |
| Fukuhara, S; Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A | 1 |
| Bayorh, MA; Eatman, D; Feuerstein, GZ; Ganafa, AA; Walton, M | 1 |
| Han, SH; Koh, KK; Lee, Y; Quon, MJ; Shin, EK | 1 |
| Kakizoe, H; Sadamatsu, K; Seto, T; Shimokawa, H; Tashiro, H; Yamamoto, K | 1 |
| Gensini, GF; Noris, P; Pecci, A; Poli, D | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Chang, LT; Chiang, CH; Chua, S; Sun, CK; Wu, CJ; Yip, HK | 1 |
| Chang, LT; Chua, S; Sun, CK; Wang, CY; Wu, CJ; Yip, HK; Youssef, AA | 1 |
| Chang, LT; Chang, NK; Chiang, CH; Lee, FY; Sheu, JJ; Sun, CK; Wu, CJ; Yip, HK; Youssef, AA | 1 |
| Chen, WP; Chiang, FT; Hsieh, CS; Hsu, KL; Hwang, JJ; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD; Tseng, YZ; Wang, DL | 1 |
| Bayorh, MA; Eatman, D; Feuerstein, GZ; Layas, MF; Mann, G | 1 |
| Chiang, FT; Hsieh, CS; Hsu, KL; Hwang, JJ; Kuo, KT; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD; Tseng, YZ | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Akbaş, H; Akkaya, B; Akman, S; Baysal, YE; Guven, AG; Kalay, S; Koyun, M | 1 |
| Huang, Y; Li, J; Lü, XW; Xu, J; Zhu, PL | 1 |
| Chang, JW; Kim, SB; Kim, SH; Lee, SK; Park, JS; Park, SK | 1 |
| Huang, Y; Lü, XW; Xing, XQ; Xu, J; Zhu, PL | 1 |
| Sikora, M; Szczepanska-Sadowska, E; Ufnal, M; Zera, T | 1 |
| Flett, AS; Godman, BB; Grosso, AM; Moon, JC; Wierzbicki, AS | 1 |
| Adachi, S; Hirao, K; Isobe, M; Ito, H; Maejima, Y; Nobori, K; Ono, Y; Suzuki, J | 1 |
| Komuro, I; Sanada, S | 1 |
| Balink, H; de Graaf, W; Grond, J; Hemmelder, MH | 1 |
| Choi, DH; Choi, JS; Yang, SH | 1 |
| Abe, S; Arikawa, T; Asanuma, H; Hikichi, Y; Inoue, T; Kikuchi, M; Kitakaze, M; Node, K; Sanada, S; Sohma, R; Taguchi, I; Toyoda, S | 1 |
| Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A | 1 |
| Morris, JK; Wald, DS; Wald, NJ | 1 |
| Abdel-Zaher, AO; Abudahab, LH; Elbakry, MH; Elkoussi, AE; Elsayed, EA | 1 |
| de Tena Gómez, MD; García Aroca, MÁ; López Soberón, E; Navarro Suay, R | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Hamel, E; Ongali, B; Royea, J; Tong, XK | 1 |
| Luteijn, JM; Morris, JK; Wald, NJ | 1 |
| Agarwal, I; Ferket, BS; Fleischmann, KE; Hunink, MG; Khanji, M; Petersen, SE | 1 |
| Abd-Eldayem, AM; Abdel-Zaher, AO; El-Refaiy, AEM; Farghaly, HSM | 1 |
| Furukubo, T; Izumi, S; Minegaki, T; Nishiguchi, K; Nitta, A; Shimada, N; Tachiki, H; Tsujimoto, M; Tsutsui, K; Uchiyama, H; Yamakawa, T; Yoshida, T | 1 |
| Becker, E; Bohrer, D; Carvalho, LM; Mattiazzi, P; Nascimento, PC; Viana, C | 1 |
| Eslahi, A; Karbalay-Doust, S; Khoshnood, O; Noorafshan, A; Shirazi, M | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
| da Silva, SVS; de Carvalho, WC; de Freitas Santos Júnior, A; de Jesus, ACL; de Sousa, TL; Dos Santos, LC; Korn, MDGA; Santos, DCMB; Souza, LA | 1 |
2 review(s) available for losartan and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Humans; Losartan; Simvastatin | 2016 |
9 trial(s) available for losartan and simvastatin
| Article | Year |
|---|---|
Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.
Topics: Aged; Angiotensin Receptor Antagonists; Biomarkers; Blood Pressure; Chemokines; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Monocytes; Receptors, Angiotensin; Simvastatin | 2004 |
Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein; Chemokine CCL2; Cross-Over Studies; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Losartan; Male; Malondialdehyde; Middle Aged; Simvastatin; Vasodilation | 2004 |
Losartan and simvastatin inhibit platelet activation in hypertensive patients.
Topics: Aged; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Simvastatin | 2004 |
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; C-Reactive Protein; CD40 Ligand; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipids; Losartan; Male; Middle Aged; Simvastatin; Solubility; Vasculitis; Vasodilation | 2007 |
Different effects of simvastatin and losartan on cytokine levels in coronary artery disease.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Cytokines; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Simvastatin; Transforming Growth Factor beta; Treatment Outcome | 2006 |
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Topics: Aged; Angiotensin Receptor Antagonists; Chronic Disease; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Simvastatin; Treatment Outcome; Ventricular Dysfunction, Left | 2011 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Method; Drug Therapy, Combination; Fatty Liver; Female; Glucose Clamp Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation Mediators; Insulin Resistance; Lipids; Losartan; Male; Middle Aged; Simvastatin; Ultrasonography | 2012 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Placebos; Simvastatin | 2012 |
Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein.
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Antihypertensive Agents; Aorta; Blood Pressure; C-Reactive Protein; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Hypertension; In Vitro Techniques; Isometric Contraction; Losartan; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Rabbits; Rats, Wistar; Simvastatin; Treatment Outcome | 2014 |
40 other study(ies) available for losartan and simvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Losartan; Male; Rats; Rats, Wistar; Simvastatin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cell Line; Chemokine CCL2; Chemokines; Down-Regulation; Drug Interactions; Endothelium, Vascular; Humans; Imidazoles; Interleukin-8; Losartan; Monocytes; NF-kappa B; Peptidyl-Dipeptidase A; Pyridines; Ramipril; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Simvastatin; Umbilical Veins | 2004 |
Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
Topics: Acetylcholine; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Body Weight; Drug Therapy, Combination; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; In Vitro Techniques; Kidney; Losartan; Male; Mesenteric Arteries; Myocardium; Nitric Oxide; Organ Size; Oxidative Stress; Prostaglandins; Rats; Rats, Inbred Dahl; Simvastatin; Sodium Chloride, Dietary; Superoxides; Thromboxane A2; Treatment Outcome; Vasoconstriction; Vasodilator Agents | 2005 |
Peripheral arteriopathy of the lower limbs in a patient with severe congenital thrombocytopenia.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensive Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Intermittent Claudication; Leriche Syndrome; Losartan; Male; Middle Aged; Simvastatin; Thrombocytopenia; Time Factors; Treatment Outcome | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Impact of simvastatin and losartan on antiinflammatory effect: in vitro study.
Topics: Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; C-Reactive Protein; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Humans; Losartan; Receptor, Angiotensin, Type 1; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2007 |
Downregulation of peroxisme proliferator activated receptor gamma co-activator 1alpha in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Down-Regulation; Losartan; Male; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; RNA, Messenger; Simvastatin; Stroke Volume; Transcription Factors; Ventricular Function, Left | 2006 |
Impact of diabetes on cardiomyocyte apoptosis and connexin43 gap junction integrity: role of pharmacological modulation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Connexin 43; Diabetes Mellitus, Experimental; Gap Junctions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Losartan; Male; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Simvastatin | 2007 |
Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes.
Topics: Angiotensin II; Animals; Calcium; Calcium Channels, L-Type; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; DNA; Losartan; Myocytes, Cardiac; NADPH Oxidases; Protein Kinase C; Rats; Rats, Wistar; Reactive Oxygen Species; Response Elements; Simvastatin; Superoxides; Transcription, Genetic | 2007 |
The effect of diet on simvastatin and losartan enhancement of endothelial function.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diet; Diet, Sodium-Restricted; Dietary Fats; Endothelium, Vascular; Epoprostenol; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Lipids; Losartan; Male; Nitric Oxide; Rats; Rats, Inbred SHR; Simvastatin; Sodium, Dietary; Superoxides; Thromboxane A2 | 2007 |
Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cells, Cultured; Fibroblasts; Heart Atria; Humans; Losartan; Muscle Cells; Phosphorylation; rac1 GTP-Binding Protein; Rats; Rats, Wistar; Signal Transduction; Simvastatin; STAT3 Transcription Factor; Ventricular Remodeling | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Beneficial effect of triple treatment plus immunoglobulin in experimental nephrotic syndrome.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Drug Therapy, Combination; Enalapril; Immunoglobulins; Immunologic Factors; Losartan; Male; Nephrotic Syndrome; Proteinuria; Rats; Rats, Wistar; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Synergism of simvastatin with losartan prevents angiotensin II-induced cardiomyocyte apoptosis in vitro.
Topics: Angiotensin II; Animals; Animals, Newborn; Apoptosis; bcl-2-Associated X Protein; Cell Culture Techniques; Cell Survival; Drug Synergism; Losartan; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Rats; Simvastatin | 2009 |
Myoglobin induces vascular cell adhesion molecule-1 expression through c-Src kinase-activator protein-1/nuclear factor-kappaB pathways.
Topics: Antioxidants; Calcium; Cells, Cultured; CSK Tyrosine-Protein Kinase; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Losartan; MAP Kinase Signaling System; Myoglobin; NF-kappa B; Protein Kinase C; Protein-Tyrosine Kinases; Simvastatin; src-Family Kinases; Transcription Factor AP-1; Vascular Cell Adhesion Molecule-1 | 2010 |
[Effects of losartan and simvastatin on collagen content, myocardial expression of MMP-2 mRNA, MMP-9 mRNA and TIMP-1 mRNA, TIMP-2 mRNA in pressure overload rat hearts].
Topics: Animals; Gene Expression Regulation; Heart Failure; Losartan; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Rats; Rats, Sprague-Dawley; Simvastatin; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2009 |
Simvastatin reduces pressor response to centrally administered angiotensin II.
Topics: Angiotensin II; Animals; Blood Pressure; Brain; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Rats; Rats, Sprague-Dawley; Simvastatin | 2010 |
Getting better value from the NHS drug budget.
Topics: Angiotensin II Type 1 Receptor Blockers; Budgets; Drugs, Generic; Health Care Reform; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Losartan; Patents as Topic; Practice Patterns, Physicians'; Prescription Drugs; Simvastatin; State Medicine; United Kingdom | 2010 |
Costarring statins with ARBs: going to be a smash hit?
Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Renin-Angiotensin System; Simvastatin; Treatment Outcome | 2011 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Chester Disease; Gated Blood-Pool Imaging; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Hypolipidemic Agents; Imidazoles; Knee Joint; Losartan; Male; Metformin; Positron-Emission Tomography; Prostatic Neoplasms; Simvastatin | 2011 |
Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Topics: Acyl Coenzyme A; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Injections, Intravenous; Losartan; Lovastatin; Male; Rats; Rats, Sprague-Dawley; Rhodamine 123; Simvastatin; Tetrazoles; Time Factors | 2011 |
Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiotonic Agents; Coronary Circulation; Disease Models, Animal; Drug Therapy, Combination; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
[Intraoperative anaphylaxis due to beta-lactams in a hypertensive patient on angiotensin ii receptor antagonists and beta-blockers].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anaphylaxis; Angiotensin II Type 1 Receptor Blockers; Bisoprolol; Breast Neoplasms; Carcinoma, Lobular; Drug Therapy, Combination; Female; Humans; Hypertension; Intraoperative Complications; Losartan; Mammaplasty; Mastectomy; Simvastatin | 2015 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Myocardial Infarction; Preventive Health Services; Simvastatin; State Medicine; Stroke; United Kingdom | 2017 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Losartan; Male; Middle Aged; Models, Economic; Primary Prevention; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2017 |
Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms.
Topics: Animals; Blood Pressure; Creatinine; Diastole; Ginkgo biloba; Glutathione; Hypercholesterolemia; Hypertension; Kidney; Lipids; Losartan; Male; Malondialdehyde; Nitric Oxide Synthase Type III; Nitrites; Plant Extracts; Protective Agents; Rats, Wistar; Simvastatin; Systole; Urea | 2017 |
Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells.
Topics: Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Losartan; Metals; Rhabdomyolysis; Rhabdomyosarcoma; Serum; Simvastatin; Superoxide Dismutase; Uremia | 2018 |
High-resolution continuum source graphite furnace atomic absorption spectrometry for screening elemental impurities in drugs to adhere to the new international guidelines.
Topics: Graphite; Losartan; Metals, Heavy; Omeprazole; Simvastatin; Spectrophotometry, Atomic | 2019 |
Comparison of the effects of pentoxifylline, simvastatin, tamoxifen, and losartan on cavernous bodies after penile fracture in rats: a stereological study.
Topics: Animals; Fibrosis; Losartan; Male; Penile Diseases; Pentoxifylline; Rats; Simvastatin; Tamoxifen | 2020 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
Effect of losartan potassium, metformin hydrochloride, and simvastatin on in vitro bioaccessibility of Cu, Fe, Mn, and Zn in oat flour from Brazil.
Topics: Avena; Brazil; Flour; Humans; Losartan; Metformin; Micronutrients; Simvastatin; Zinc | 2022 |